Relevance of augmented kisspeptin signaling through H³⁶⁴ KISS1R in central precocious puberty.

Banerjee AA, Bhanarkar SR, Keshwani R, Pande S, Modi DN, Mehta A, Bombe S, Pathak BR, Joshi B, Tandon D, Patil A, Begum S and 4 more

Show all authors

Chauhan S, Mahale SD, Rao S, Surve SV

Gene20 Nov 2023Cited by 3 (Europe PMC)

PMID37981083DOI10.1016/j.gene.2023.148016PepBankPUB-37981083

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelCase report or seriesOther
In a girl with idiopathic central precocious puberty, GnRH analog treatment suppressed circulating Kp-10 levels.
In plain wordsIn a girl with early puberty, GnRH analog treatment lowered the body's own kisspeptin‑10 levels.
Peptide
Kisspeptin-10
Outcome
DecreaseCirculating Kp-10 after GnRH analog treatment
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
It was observed that GnRHa treatment resulted in suppression of circulating levels of Kp-10, NKB and NPY.
1 context sentence(design, population, supporting numbers)
Summary · context
Plasma levels of Kp-10, NKB and NPY before and after GnRH analog (GnRHa) treatment, were determined by ELISA.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3798108301

Studies that did not test the peptide alone2

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

02LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Activity measurement
In CHO cells, the H364 KISS1R variant showed enhanced signalling at high Kp-10 doses compared with the L364 variant.
In plain wordsIn lab cells, a receptor variant from a girl with early puberty responded more strongly to high doses of kisspeptin‑10.
Peptide
Kisspeptin-10
Outcome
IncreaseKp-10 signalling through H364 KISS1R variant
Study
n: not reported in source
CHO cells expressing KISS1R variants
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Source sentences
Summary
Structure-function studies revealed that, although the receptor expression in H³⁶⁴ KISS1R was comparable to L³⁶⁴ KISS1R, there was an enhanced signalling response through this variant at high doses of Kp-10.
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-3798108302
03LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Mechanism
In CHO cells, receptor expression of the H364 KISS1R variant was comparable to the L364 variant.
In plain wordsIn lab cells, the variant receptor was present at about the same level as the usual receptor.
Peptide
Kisspeptin-10
Outcome
No significant changeReceptor expression of H364 versus L364 KISS1R
Study
n: not reported in source
CHO cells expressing KISS1R variants
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Source sentences
Summary
Structure-function studies revealed that, although the receptor expression in H³⁶⁴ KISS1R was comparable to L³⁶⁴ KISS1R, there was an enhanced signalling response through this variant at high doses of Kp-10.
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-3798108303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.